Atara Biotherapeutics (FRA:AT2) Ending Cash Position : €23.83 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Atara Biotherapeutics Ending Cash Position?

Atara Biotherapeutics's Ending Cash Position for the quarter that ended in Dec. 2023 was €23.83 Mil.

Atara Biotherapeutics's quarterly Ending Cash Position increased from Jun. 2023 (€42.50 Mil) to Sep. 2023 (€60.85 Mil) but then declined from Sep. 2023 (€60.85 Mil) to Dec. 2023 (€23.83 Mil).

Atara Biotherapeutics's annual Ending Cash Position declined from Dec. 2021 (€95.12 Mil) to Dec. 2022 (€87.88 Mil) and declined from Dec. 2022 (€87.88 Mil) to Dec. 2023 (€23.83 Mil).

Atara Biotherapeutics Ending Cash Position Historical Data

The historical data trend for Atara Biotherapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atara Biotherapeutics Ending Cash Position Chart

Atara Biotherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

68.14

165.88

95.12

87.88

23.83

Atara Biotherapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Ending Cash Position	Get a 7-Day Free Trial															87.88	45.66	42.50	60.85	23.83

Atara Biotherapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Atara Biotherapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	85.362	+	-61.532
	=	23.83

Atara Biotherapeutics's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	59.546	+	-35.716
	=	23.83

Atara Biotherapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Atara Biotherapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Atara Biotherapeutics (FRA:AT2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atara Biotherapeutics Inc (FRA:AT2) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

ATRA:USA AT2:Germany

Address

2380 Conejo Spectrum St, Suite 200, Thousand Oaks, CA, USA, 91320

Website

https://www.atarabio.com

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Atara Biotherapeutics (FRA:AT2) Headlines

No Headlines